SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-19-150602
Filing Date
2019-05-17
Accepted
2019-05-17 16:31:55
Documents
1
Group Members
COLUMN GROUP GP, LPCOLUMN GROUP II GP, LPCOLUMN GROUP II, LPCOLUMN GROUP MANAGEMENT, LPDAVID V. GOEDDELPETER SVENNILSONPONOI CAPITAL II, LPPONOI CAPITAL, LPPONOI II MANAGEMENT, LLCPONOI MANAGEMENT, LLCTIM KUTZKEY

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d686173dsc13da.htm SC 13D/A 217015
  Complete submission text file 0001193125-19-150602.txt   218867
Mailing Address 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158 415-865-2050
COLUMN GROUP L P (Filed by) CIK: 0001347769 (see all company filings)

IRS No.: 000000000
Type: SC 13D/A

Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Subject) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90978 | Film No.: 19836210
SIC: 2834 Pharmaceutical Preparations